| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q2 2021 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMAG PHARMACEUTICALS INC | 2 | Q3 2020 | 5.3% |
| THERAVANCE BIOPHARMA INC | 2 | Q3 2020 | 4.5% |
| INTERCEPT PHARMACEUTICALS IN | 2 | Q3 2020 | 2.8% |
| MICROCHIP TECHNOLOGY INC | 2 | Q3 2020 | 2.7% |
| INFINERA CORPORATION | 2 | Q3 2020 | 2.4% |
| NANTHEALTH INC | 2 | Q3 2020 | 2.5% |
| ENCORE CAP GROUP INC | 2 | Q3 2020 | 1.7% |
| NOVAVAX INC | 2 | Q3 2020 | 0.7% |
| RADIUS HEALTH INC | 2 | Q3 2020 | 0.5% |
| ENCORE CAP GROUP INC | 2 | Q3 2020 | 0.6% |
View Context Partners Fund, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| D/A | 2024-01-23 |
| D/A | 2023-01-25 |
| D/A | 2022-01-27 |
| D/A | 2021-06-30 |
| D/A | 2021-01-27 |
| 13F-HR | 2020-11-16 |
| D/A | 2020-01-29 |
| D/A | 2019-01-28 |
| D/A | 2018-11-05 |
| 13F-HR | 2018-11-01 |
View Context Partners Fund, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.